Skip to main content
European Commission logo
Coronavirus Global R&I Collaboration Portal


Members (2)

From across Europe and beyond, and from a variety of backgrounds, our members share many common goals. Our members’ diversity, expertise and openness to collaborate is our strength. Search our members list here. Filter using our search options. All members are encouraged to network and develop as a community that fosters collaboration. Find your match, share, engage and complement expertise.

Showing 1-2 of 2 members.

Likui Wang,Institute of Microbiology, Chinese Academy of Sciences

Higher education
Home country
Type of research activities
Basic research
Fields of research
Medical and health sciences
Specialisation and expertise

The global vaccinology training website will help identify further additional vaccinology courses that will eventually be listed on the electronic registry. A primary aim of the platform is to facilitate identification of suitable training by those looking for such courses. This platform will also help strengthen a workforce network to advance vaccinology around the global. The studies of transmission mechanism of emerging viruses have provided important basis for the policy maker from sciences to control and prevent the emerging infectious diseases, especially the elucidation of the relationship between novel coronavirus infection

English, Russian, Chinese


Business enterprise
Home country
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Economics and Business, Natural sciences, Medical and health sciences
Specialisation and expertise

We are the developer of an innovative technology for the production of a completely new highly effective active substance. These regenerating products are extremely effective in treatment of liver cirrhosis of various etiologies previously officially considered incurable (ascites goes away after 15 days, cirrhosis changes into fibrosis after 30-50 days, the period of complete hepatic regeneration is about 4 months). They are also effective against genital herpes virus (4-6 months), effective against hepatitis of various etiologies, including such as B, C, D ( viral load is reduced by half every 26 days, after a course of therapy, the virus is not detected in the blood, the patient ceases to be a virus carrier), drugs restore the liver in case of fatty hepatosis, pulmonary tuberculosis including MDR TB/ XDR TB (after 26 days an active form of stage 4 changes into stage 2-3 of latent form), lymphosarcoma, fibroma, myoma and pyelonephritis. The drugs prevent diabetic foot gangrene extremities. After the therapy patients no longer need previously recommended heart bypass surgery. The drug restores the function of the pancreas, and gives a complete restoration of long-term erectile dysfunction. The condition of patients with Alzheimer disease, Down's syndrome, encephalopathy, encephalitis and other diseases improves significantly without any side effects. The drugs have a strong antifibrotic effect, they dissolve scars on heart after myocardial infarction. Heart tissue completely regenerates within 6 months. This is only what we have studied so far.  We have strong assumptions that our medications can also effectively affect the activity of the COVID-19 coronavirus, as well as other viruses and infections. We are interested in partners and research of our drugs.

Russian, English, Spanish, French
The portal is now open.

Join this community of researchers, publish your member profile and team up for new collaboration opportunities.

Become a member